2020
DOI: 10.11604/pamj.2020.36.294.25065
|View full text |Cite
|
Sign up to set email alerts
|

Clinical characteristics and treatment outcomes of angioid streak associated choroidal neovascular membrane (AS-CNV): a Zambian case series

Abstract: This case series illustrates clinical features and treatment outcomes of angioid streak associated CNV (AS-CNV) in 3 consecutive patients. Mean age of patients was 43.2 years with one female patient. Bilateral CNV was present in one patient. Comet-tail lesions were present in all cases. No underlying systemic association was found in any of the patients. All patients were treated with 3 loading doses of anti-VEGF injections (ranibizumab in two and aflibercept was used in one case). Subretinal fluid resolved in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…The three main anti-VEGF agents that have been used as monotherapy for the treatment of CNV secondary to ASs are ranibizumab, aflibercept, and off-label bevacizumab [ 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 ]. Numerous studies and reports have been published describing the visual and anatomical outcomes of these three anti-VEGF agents [ 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 ,…”
Section: Narrative Review Findingsmentioning
confidence: 99%
See 1 more Smart Citation
“…The three main anti-VEGF agents that have been used as monotherapy for the treatment of CNV secondary to ASs are ranibizumab, aflibercept, and off-label bevacizumab [ 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 ]. Numerous studies and reports have been published describing the visual and anatomical outcomes of these three anti-VEGF agents [ 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 ,…”
Section: Narrative Review Findingsmentioning
confidence: 99%
“…None of these reports were randomized, double-blind trials. They were either retrospective case reports or case series with a variable number of eyes enrolled and variable follow-up [ 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 ]. Nevertheless, they all demonstrate that all three anti-VEGF agents manage to at least stabilize the visual acuity regardless of the underlying systemic cause of ASs [ 3 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , …”
Section: Narrative Review Findingsmentioning
confidence: 99%